DDDavid B. Donner

David B. Donner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David B. Donner has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Ann C. Griffin

    Cancer Registry, University of California, San Francisco, San Francisco, Calif

    1 shared publication
  • Ariel Fernando Castro

    Laboratorio de Transducción de Señales y Cáncer, Departamento de Bioquímica y Biología Molecular, Facultad Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

    1 shared publication
  • Carla P. Martins

    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America

    1 shared publication
  • Carlos Farkas

    Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

    1 shared publication
  • Daniel T. Ruan

    Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA

    1 shared publication
  • David Escobar

    Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

    1 shared publication

Latest Publications

  • Open Access

    Wild Type p53 Transcriptionally Represses the SALL2 Transcription Factor under Genotoxic Stress

    by Carlos Farkas, Carla P. Martins, David Escobar, Matias I. Hepp, David B. Donner, Ariel F. Castro, Gerard Evan, José L. Gutiérrez, Robert Warren, Roxana Pincheira

    SALL2- a member of the Spalt gene family- is a poorly characterized transcription factor found deregulated in various cancers, which suggests it plays a role in the disease. We previously identified SALL2 as a novel interacting protein of neurotrophin receptors and showed that it plays a role in neuronal function, which does not necessarily explain why or how SALL2 is deregulated in cancer. Previous evidences indicate that SALL2 gene is regulated by the WT1 and AP4 transcription factors. Here, we identified SALL2 as a novel downstream target of the p53 tumor suppressor protein. Bioinformatic analysis of the SALL2 gene revealed several putative p53 half sites along the promoter region. Either overexpression of wild-type p53 or induction of the endogenous p53 by the genotoxic agent doxorubicin repressed SALL2 promoter activity in various cell lines. However R175H, R249S, and R248W p53 mutants, frequently found in the tumors of cancer patients, were unable to repress SALL2 promoter activity, suggesting that p53 specific binding to DNA is important for the regulation of SALL2. Electrophoretic mobility shift assay demonstrated binding of p53 to one of the identified p53 half sites in the Sall2 promoter, and chromatin immunoprecipitation analysis confirmed in vivo interaction of p53 with the promoter region of Sall2 containing this half site. Importantly, by using a p53ERTAM knockin model expressing a variant of p53 that is completely dependent on 4-hydroxy-tamoxifen for its activity, we show that p53 activation diminished SALL2 RNA and protein levels during genotoxic cellular stress in primary mouse embryo fibroblasts (MEFs) and radiosensitive tissues in vivo. Thus, our finding indicates that p53 represses SALL2 expression in a context-specific manner, adding knowledge to the understanding of SALL2 gene regulation, and to a potential mechanism for its deregulation in cancer.


  • Sall2 is a novel p75NTR‐interacting protein that links NGF signalling to cell cycle progression and neurite outgrowth

    by Roxana Pincheira, Melinda Baerwald, James D Dunbar, David B Donner

    By screening a fetal brain two‐hybrid library with the death domain of the p75 neurotrophin receptor (NTR), we identified the Sall2 transcription factor as a novel interacting protein. Sall2 is a unique member of the Sall gene family, which is believed to be a tumour suppressor. Here, we show that Sall2 contains a p75NTR interaction domain not found in other Sall proteins and that p75NTR/Sall2 complexes co‐immunoprecipitate from brain lysates. NGF dissociates p75NTR/Sall2 complexes and activates TrkA, which has an obligate function in the nuclear translocation of Sall2. NGF also increases Sall2 expression and this is mediated by p75NTR, but may not require TrkA. Depletion of Sall2 from cells decreases the expression and activity of p21WAF1/CIP1, as well as the ability of NGF to induce growth arrest and the development of neurites. Overexpression of Sall2 activates p21WAF1/CIP1, induces growth arrest, and promotes neurite outgrowth independently of NGF. These data establish Sall2 as a link between NTRs and transcriptional events that regulate the growth and development of neuronal cells.


  • Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAFV600E positive papillary thyroid cancers

    by Daniel T. Ruan, Robert S. Warren, Jacob Moalem, Ki-Wook Chung, Ann C. Griffin, Wen Shen, Quan-Yang Duh, Eric Nakakura, David B. Donner, Elham Khanafshar, et al.